Maven Securities LTD Reduces Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Maven Securities LTD decreased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 81.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,000 shares of the company’s stock after selling 325,000 shares during the quarter. Maven Securities LTD’s holdings in Roivant Sciences were worth $887,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Roivant Sciences in the fourth quarter worth $52,443,000. Invesco Ltd. increased its holdings in shares of Roivant Sciences by 49.7% in the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock valued at $112,563,000 after purchasing an additional 3,159,603 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the period. TOMS Capital Investment Management LP boosted its holdings in Roivant Sciences by 46.6% during the fourth quarter. TOMS Capital Investment Management LP now owns 5,885,000 shares of the company’s stock worth $69,620,000 after buying an additional 1,870,000 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Roivant Sciences by 104.4% during the fourth quarter. Marshall Wace LLP now owns 2,946,954 shares of the company’s stock worth $34,862,000 after buying an additional 1,505,062 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

ROIV stock opened at $10.76 on Wednesday. The firm has a fifty day moving average price of $10.49 and a two-hundred day moving average price of $11.10. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06. The firm has a market cap of $7.68 billion, a price-to-earnings ratio of -71.73 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

ROIV has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th.

Insiders Place Their Bets

In related news, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. The trade was a 58.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the transaction, the chief operating officer now directly owns 1,116,345 shares in the company, valued at approximately $11,409,045.90. The trade was a 8.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,669,500 shares of company stock worth $18,064,847 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.